Drug Trial Radar · NCT06820463
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
390
Planned (sponsor's estimate)
Start
Apr 24, 2025
Primary completion
Mar 2028
Study completion Apr 2028
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into 3 groups called treatment arms where one group will receive one of two optimized doses of telisotuzumab adizutecan from the dose escalation phase with FOLFOX and bevacizumab or 5FU/LV and panitumumab, or a comparator of FOLFOX and bevacizumab or panitumumab. Approximately 390 adult participants with mCRC will be enrolled in the study in 100 sites worldwide. In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive FOLFOX or receive 5FU/LV, but with one of two optimized doses of telisotuzumab adizutecan, or a comparator of FOLFOX and bevacizumab/pantitumumab. The study will run for a duration of approximately 6 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Conditions
- Metastatic Colorectal Cancer
Interventions
Telisotuzumab AdizutecanDrug
Intravenous (IV) Infusion
FluorouracilDrug
IV Infusion; IV Injection
OxaliplatinDrug
IV Infusion
LeucovorinDrug
IV Infusion; IV Injection
BevacizumabDrug
IV Infusion
PanitumumabDrug
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response (OR) as Assessed by the Investigator confirmed complete response (CR) or partial response (PR) as assessed by the investigator per response evaluation criteria in solid tumors (RECIST), version 1.1.Time frame: Up to 24 Weeks
- Number of Participants with Adverse Events (AE)sTime frame: Up to Approximately 6 Years
Locations
82 sites in 15 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center /ID# 270255
Duarte, California · Recruiting
UCLA - Santa Monica /ID# 270621
Santa Monica, California · Recruiting
Yale New Haven Hospital /ID# 270565
New Haven, Connecticut · Recruiting
AdventHealth Orlando /ID# 270789
Orlando, Florida · Recruiting
Northwest Georgia Oncology Centers /ID# 270245
Marietta, Georgia · Recruiting
University of Chicago Medical Center /ID# 271688
Chicago, Illinois · Recruiting
Hope And Healing Cancer Services /ID# 271562
Hinsdale, Illinois · Recruiting
Dana-Farber Cancer Institute /ID# 270624
Boston, Massachusetts · Recruiting
University Of Michigan /ID# 270790
Ann Arbor, Michigan · Recruiting
Saint Lukes Hospital of Kansas City /ID# 270633
Kansas City, Missouri · Recruiting
Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646
Omaha, Nebraska · Recruiting
University of North Carolina at Chapel Hill /ID# 267786
Chapel Hill, North Carolina · Recruiting
Oncology Hematology Care - Eastgate /ID# 271493
Cincinnati, Ohio · Recruiting
Texas Oncology - Austin Midtown /ID# 271354
Austin, Texas · Recruiting
Texas Oncology - Deke Slayton Cancer Center /ID# 271355
Webster, Texas · Recruiting
Virginia Cancer Specialists - Fairfax /ID# 271351
Fairfax, Virginia · Recruiting
University Of Washington /ID# 271298
Seattle, Washington · Recruiting
Macquarie University /ID# 271514
Sydney, New South Wales, Australia · Recruiting
Mater Misericordiae /ID# 270694
South Brisbane, Queensland, Australia · Recruiting
The Queen Elizabeth Hospital /ID# 270693
Woodville South, South Australia, Australia · Recruiting
Austin Health /ID# 270692
Heidelberg, Victoria, Australia · Recruiting
One Clinical Research /ID# 270695
Nedlands, Western Australia, Australia · Recruiting
Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 268874
Salzburg, Austria · Recruiting
Medizinische Universitaet Wien /ID# 268872
Vienna, Austria · Recruiting
Medizinische Universitaet Graz /ID# 268876
Graz, Styria, Austria · Recruiting
Instituto D Or De Pesquisa E Ensino - Regional Sao Paulo /ID# 270546
São Paulo, Brazil · Recruiting
Nucleo De Pesquisa Clinica Da Rede Sao Camilo /ID# 272311
São Paulo, Brazil · Recruiting
Hospital Sao Rafael /ID# 271681
Salvador, Estado de Bahia, Brazil · Recruiting
Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 270147
Ijuí, Rio Grande do Sul, Brazil · Recruiting
Hospital De Amor /ID# 271874
Barretos, São Paulo, Brazil · Recruiting
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 271651
São José do Rio Preto, São Paulo, Brazil · Recruiting
Arthur J.E Child Comprehensive Cancer Centre /ID# 269809
Calgary, Alberta, Canada · Recruiting
Cross Cancer Institute. /ID# 272711
Edmonton, Alberta, Canada · Recruiting
London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 270680
London, Ontario, Canada · Recruiting
Princess Margaret Cancer Centre /ID# 268715
Toronto, Ontario, Canada · Recruiting
Universite de Montreal - Hopital Maisonneuve-Rosemont /ID# 271368
Montreal, Quebec, Canada · Recruiting
Masarykuv onkologicky ustav v Brne /ID# 268779
Brno, Czechia · Recruiting
Fakultni nemocnice Hradec Kralove - Sokolska /ID# 268773
Hradec Králové, Czechia · Recruiting
Vseobecna Fakultni nemocnice v Praze /ID# 268775
Prague, Praha 17, Czechia · Recruiting
Fakultni nemocnice Motol a Homolka /ID# 268776
Prague, Praha 5, Czechia · Recruiting
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.